Search
for
Sort by
Research 361–390 of 369
- TGF-β2 and collagen play pivotal roles in the spheroid formation and anti-aging of human dermal papilla cells
- Selenium Compounds and Their Bioactivities: Molecular Mechanisms and Prospects for Functional Food and Therapeutic Applications
- Cutaneous Lymphadenoma Is a Distinct Trichoblastoma-like Lymphoepithelial Tumor With Diffuse Androgen Receptor Immunoreactivity, Notch1 Ligand in Reed-Sternberg–like Cells, and Common EGFR Somatic Mutations
- Identification of key pathways and genes that regulate cashmere development in cashmere goats mediated by exogenous melatonin
- Vitamin A resolves lineage plasticity to orchestrate stem cell lineage choices
- Biosynthetic studies through feeding experiments in Eclipta prostrata (L.) L. hairy roots
- Serum phoenixin-14 and phoenixin-20 concentrations in polycystic ovary syndrome: Associations with anti-Müllerian hormone and diagnostic utility
- Titanium dioxide nanoparticles: a promising candidate for wound healing applications
- Dermal fibroblasts: the terminology, heterogeneity of subpopulations and common properties
- Abstract 1677: Epithelial hyperplasia induced by a selective B-Raf inhibitor, WYE-130600
- The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors
- Dermatologic Side Effects of Systemic Targeted Anticancer Therapy
- Sorafenib-induced eruption resembling pityriasis rubra pilaris
- Cutaneous adverse effects of targeted therapies
- 329 Mechanisms of Cutaneous Adverse Events during Targeted Cancer Therapy
- Retinoid-mediated stimulation of steroid sulfatase activity in myeloid leukemic cell lines requires RARα and RXR and involves the phosphoinositide 3-kinase and ERK-MAP kinase pathways
- Self‐Assembled Peptide Hydrogels Loaded with Umbilical Cord‐Derived Mesenchymal Stem Cells Repairing Injured Endometrium and Restoring Fertility
- Biological therapy in the treatment of melanoma
- From bench to babies – drug development for male subfertility
- The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: the Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma
- Tumor necrosis factor inhibitors and janus kinase inhibitors in the treatment of cicatricial alopecia: A systematic review
- Purified Vitexin Compound 1 Inhibits UVA-Induced Cellular Senescence in Human Dermal Fibroblasts by Binding Mitogen-Activated Protein Kinase 1
- 696 MEK and BRAF inhibitors augment the production and accumulation of sebum in hamster sebocytes
- BRAF Inhibitor Dabrafenib in Patients with Metastatic <i>BRAF</i>-Mutant Thyroid Cancer
- Molecular targeted therapies for cancer: Sorafenib mono�therapy and its combination with other therapies (Review)
- Management of Toxicities of Targeted Therapies
- Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
- Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
- Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer
- Advances in the Management of Cutaneous Toxicities of Targeted Therapies